Two simple, sensitive and precise ultraviolet-visible spectrophotometric methods have been developed for the determination of rivaroxaban in pharmaceutical dosage forms. The spectrophotometric detection was carried out at an absorption maximum of 671.5 nm and 559 nm for method A and method B using 3-Methyl-2- benzothiazolinone hydrazone Hydrochloride (MBTH) and Sodium 1,2-naphthoquinone-4-sulfonate (NQS) reagents. The developed methods were validated according to ICH Q2R1 guidelines. The detector response for the rivaroxaban was linear over the concentration range with a correlation coefficient 10 to 50 µg/mL, 0.9993 and 10 to 60 µg/mL, 0.9996 for method A and method B respectively. The percent recoveries were found between 98.8 to 102.73%, indicating that the methods are precise and reproducible. The limit of detection and limit of quantification were found to be 0.008 μg/mL and 0.001 μg/mL and 0.033 μg/mL and 0.026 μg/mL for method A method B respectively. The methods have been successfully employed for the analysis of the marketed formulation of rivaroxaban tablets ‘RIVALTO’ by Synokem Pharmaceuticals Ltd. and the percentage purity was found to be 99.76% for both methods. The proposed methods can be successfully employed for the routine analysis of rivaroxaban in quality control laboratories.
Loading....